Abstract Chronic β-adrenoceptor antagonist (β-blocker) treatment in patients is associated with a potentially antiarrhythmic prolongation of the atrial action potential duration (APD), which may involve remodelling of repolarising K + currents. The aim of this study was to investigate the effects of chronic β-blockade on transient outward, sustained and inward rectifier K + currents (I TO , I KSUS and I K1 ) in human atrial myocytes and on the expression of underlying ion channel subunits. Ion currents were recorded from human right atrial isolated myocytes using the whole-cell-patch clamp technique. Tissue mRNA and protein levels were measured using real time RT-PCR and Western blotting. Chronic β-blockade was associated with a 41% reduction in I TO density: 9.3±0.8 (30 myocytes, 15 patients) vs 15.7±1.1 pA/pF (32, 14), p<0.05; without affecting its voltage-, time-or rate dependence. I K1 was reduced by 34% at −120 mV (p<0.05). Neither I KSUS , nor its increase by acute β-stimulation with isoprenaline, was affected by chronic β-blockade. Mathematical modelling suggested that the combination of I TO -and I K1 -decrease could result in a 28% increase in APD 90 . Chronic β-blockade did not alter mRNA or protein expression of the I TO pore-forming subunit, Kv4.3, or mRNA expression of the accessory subunits KChIP2, KChAP, Kvβ1, Kvβ2 or frequenin. There was no reduction in mRNA expression of Kir2.1 or TWIK to account for the reduction in I K1 . A reduction in atrial I TO and I K1 associated with chronic β-blocker treatment in patients may contribute to the associated action potential prolongation, and this cannot be explained by a reduction in expression of associated ion channel subunits.
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with significant morbidity and mortality [3] . Beta adrenoceptor antagonists (β-blockers) are used in the treatment of AF to control the ventricular rate, and they also exert atrial anti-arrhythmic effects [22] . The mechanisms underlying these atrial antiarrhythmic effects are multifactorial [32, 36] , but there is evidence to suggest that long-term treatment with β-blockers can alter atrial cellular electrophysiology by prolonging the action potential duration (APD) and effective refractory period [29, 35] and, therefore, potentially inhibiting intraatrial reentry.
This "pharmacological remodelling" [35] of atrial action potentials in patients treated chronically with β-blockers was initially demonstrated by our group to be associated with a reduction in the density of the atrial transient outward K + current, I TO . However, the electrophysiological and molecular mechanisms of this ion current change are unknown. Thus, the effects of chronic β-blockade on characteristics of human atrial I TO other than its amplitude, such as voltage dependence and kinetics, have not yet been investigated. Furthermore, the effects of chronic β-blockade on the expression of ion channel proteins which carry and modulate this current, proteins known to be associated with electrophysiological remodelling in AF and other cardiac pathologies [24] , also have not yet been studied.
Preliminary data from our laboratory have suggested that chronic β-blockade may also reduce the human atrial inward rectifier K + current, I K1 , since the atrial cellular input resistance was reduced in patients taking β-blockers [35] , although this current was not measured directly. Since there is increasing evidence to suggest that an increase in I KI may be a crucial determinant of the pro-arrhythmic atrial APD shortening seen in AF remodelling [28] , it is important to establish the effects of chronic β-blockade on I K1 and on the expression of ion channel proteins associated with this current. The aims of this study, therefore, were to investigate the effects of chronic β-blockade in patients on the time-and voltage-dependent characteristics of the main repolarising K + currents in the human atrium and on the expression of their underlying ion channel subunits, and also to investigate the likely effects of these ion current changes on the atrial action potential.
Methods

Human atrial myocyte isolation
Right atrial appendage tissues were obtained from adult patients undergoing cardiac surgery, who were in sinus rhythm with no history of AF, and either treated with a β-blocker for a minimum of 4 weeks prior to surgery or not treated with a β-blocker. All procedures were approved by the institutional ethics committee (99MC002) and informed consent was obtained from all patients. The investigation conforms with the principles outlined in the Declaration of Helsinki. Atrial myocytes were isolated by enzymatic dissociation and mechanical disaggregation, as described in detail previously [33] . Briefly, tissue chunks were shaken for 45 min in a low [Ca 2+ ] (50 μM) solution containing protease (4 U/ml Type XXIV, Sigma). Protease was then replaced by collagenase (400 U/ml type 1, Worthington), which was exchanged three times, at 15-min intervals. At each exchange, cells were separated by filtration through nylon gauze and centrifugation at 40g for 2 min, and washed of residual enzyme in a high [ Voltage-dependent activation of I TO was measured by stimulating cells at 0.3 Hz from a holding potential of −50 mV, with voltage pulses of 100-ms duration increasing in 10 mV steps from −40 to +60 mV. I TO amplitude was calculated as the peak outward current minus end pulse current. I KSUS , considered to reflect mainly the ultra-rapid delayed rectifier K + current, I Kur [25] , was measured as the end pulse current. Voltage-dependent inactivation of I TO was measured using a 1-s pre-pulse which was increased from −90 to +60 mV in 10 mV steps, followed by a second, 100-ms pulse, to +60 mV. I TO reactivation was measured using a standard S 1 -S 2 pulse protocol with an initial inter-pulse interval of 500 ms, which was reduced in 50-ms intervals to 150 ms, and then by 10-ms intervals to 10 ms. I TO rate dependence was measured using six trains of eight pulses at 75-500 beats/min. Barium (0.5 mM)-sensitive I K1 voltagedependent activation was determined using 500-ms voltage pulses increasing from −120 to +60 mV in 10 mV steps. In a subset of cells, the effect of acute β-adrenoceptor stimulation with isoprenaline (ISO) on I K1 (in the absence of Ba 2+ ), I TO and/or I KSUS , was assessed. ISO was used at 1 μM; close to E max concentration for human atrial I Kur [20] .
Mathematical modelling
To investigate the potential contribution of changes in ion currents to the action potential (AP) configuration, such changes were simulated using a well-established mathematical model of the human atrial AP; described in Courtemanche et al. [6] and implemented using the CESE Pro 1.4.8 modelling software (Simulogic Inc., Halifax, Canada). Since the typical AP configuration recorded in the human atrial cells from our laboratory [35] is type 3 (or "no dome" [8] ), and the Courtemanche model typically produces type 1 APs (or "spike and dome") [8] , we modified the model to produce "no dome" APs that mimicked those recorded in our laboratory, as follows. The L-type Ca 2+ current (I CaL ) and I KSUS are the largest two currents that contribute to the plateau ("dome") phase of the action potential in the Courtemanche model: see Fig. 2 of [32] and Fig. 14 of [6] . The peak conductance of I CaL in the Courtemanche model (0.124 nS/pF) is larger than that typically recorded in our laboratory (0.099 nS/pF; [35] ), and the peak conductance of I Kur in the Courtemanche model (0.054 nS/pF) is smaller than that recorded in cells in the present study (0.075 nS/pF). Therefore, I CaL and I Kur conductances were decreased and increased, respectively, in steps of 10%, until the resulting action potential closely resembled that from a representative cell obtained from a patient not treated with a β-blocker: Fig. 1a of [35] . This was achieved with a 50% scaling of I CaL and 150% I Kur , i.e., peak conductances of 0.062 nS/pF and 0.081 nS/pF, respectively.
Quantitative real-time PCR
Human atrial tissue samples were stored at −20°C in RNAlater solution (Quiagen), before cryosectioning at 20 μm. Total RNA was extracted using RNeasy Mini Kit (Quiagen) and reverse transcribed with Superscript III reverse transcriptase (Invitrogen), using random hexamer priming and a PCR thermocycler (Thermohybaid PCR Express). The relative abundance of cDNA was determined using an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems), Power SYBR Green PCR MasterMix (Applied Biosystems) and primer assays (10× QuantiTect, Quiagen or Applied Biosystems) (Tables 1 and 2 ). Samples were tested in triplicate for each primer with a 40-cycle PCR reaction followed by melting curves. Negative controls consisted of molecular-grade water. Mean threshold cycles (Ct) values were determined and ΔCt derived relative to one tissue sample used as an internal calibrator for each primer reaction. cDNA abundance for each tissue sample (a) was expressed relative to mean abundance of 28S and GAPDH (b) for that sample, using the equation: relative abundance= Ea ΔCta
/Eb
ΔCtb . E = efficiency of the PCR reaction and was determined from √Fn/F-2n , where F = fluorescence at the end of each elongation step and n = cycle number.
Western blotting
Human atrial tissue samples were homogenised for 90 s with an Ultraturrax T8 homogeniser (VWR) in 1 ml of homogenisation buffer containing: 15 μl protease inhibitor (Sigma P8340), NaCl 150 mM, KCl 5.4 mM, MgCl 2 1.2 mM, NaHEPES 5 mM, Glucose 10 mM, CaCl 2 1.0 mM; pH 7.4, and stored at −80°C. Kv4.3 and GAPDH protein levels were measured using sodium dodecyl sulphate polyacrylamide gel electrophoresis, immunoblotting and optical densitometry. Tissue samples were blinded with respect to β-blocker status and randomised so that two samples from β-blocked and two from non-β-blocked patients were loaded onto each gel, at concentrations which we first established to result in a linear relationship with optical density (total protein load of 5-10 μg per lane). Electrophoresis and immunoblotting were performed using the NuPAGE system (Invitrogen) with 4-12% gradient Bis-Tris NuPAGE gels and molecular weight marker Magic Mark Western Standard. Protein immunodetection was performed using the Invitrogen Western Breeze kit unless otherwise stated and analysed using Quantity One software (BIORAD). Blots were incubated overnight with monoclonal anti-Kv4.3 (Neuromab) at 1:133 or anti-GAPDH (mAbcam 9484) at 1:20,000. Western blotting controls were performed using rabbit and rat brain or lung tissues. All procedures conformed with the Institutional Guidelines for the Care and Use of Animals and with the Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. A New Zealand white rabbit was killed with an intravenous injection of 100 mg/kg pentobarbital sodium (UK Project Licence No. PPL60/3538), and a Wistar rat was killed by cervical dislocation in accordance with schedule 1. Tissue homogenates were used to compare bands generated by the monoclonal primary antibody (Neuromab anti-Kv4.3) plus secondary antibodies with secondary antibody alone and also to compare a polyclonal anti-Kv4.3 (Alomone) at 1:1,600 with a solution 
Statistical analysis
Comparisons between patient groups for current and ion channel expression were made using Student's t tests, with Graphpad Prism software. Multiple linear regression was performed using Stata Version 10, Stata Corp., College Station, TX, USA. Statistical significance was taken as p<0.05. Table 3 shows the patients' clinical characteristics and a comparison between treatment and non-treatment with a β-blocker. The majority of patients underwent coronary artery bypass graft surgery (89%) and had angina (88%). LV function was normal in 74% of patients. Of the patients treated with a β-blocker, 95% received a cardiac selective β 1 -adrenoceptor antagonist (atenolol or bisoprolol), and two patients received carvedilol, which additionally antagonises β 2 -and α 1 -receptors. No patient was given sotalol (which has additional class III activity). Patients treated and not treated with a β-blocker were generally of similar age, malefemale ratio and disease history (Table 3) . Those receiving a β-blocker had a lower incidence of calcium channel blocker use and a lower heart rate ( Table 3) .
Results
Patient characteristics
Chronic β-blockade reduced the density of human atrial I TO and I K1 , but not I KSUS Figure 1a shows the representative current traces of I TO and I KSUS voltage-dependent activation in myocytes of similar capacitance from a non-β-blocked patient and a β-blocked patient. There was a significant reduction in mean I TO density at all voltages from +10 to +60 mV associated with chronic β-blockade (Fig. 1b) . Peak I TO density at +60 mV was 41% lower in myocytes from patients treated with a β-blocker compared to non-β-blocked patients (Fig. 1c) . There was no significant difference in the mean capacity of these cells between patients treated and not treated with a β-blocker (67 ±4 vs 76±3 pF; p>0.05). Single linear regression analysis of the effects of chronic β-blockade on I TO demonstrated a change in current density of −4.14 pA/pF (95% CI −7.50 to −0.77, p<0.05). There was a significant reduction in I TO density of −4.19 pA/pF (95% CI −7.88 to −0.49, p<0.05) in association with chronic β-blockade after adjusting for calcium channel blocker use. In a separate model, adjusting for heart rate, chronic β-blockade was not statistically significantly associated with I TO density, −1.61 pA/pF (95% CI −6.35 to 3.14, p=0.49). There was no difference in peak I KSUS density, recorded in the same cells, between β-blocked and non-β-blocked patients (Fig. 1c) . Figure 2 shows the mean current-voltage relationships for Ba 2+ -sensitive I K1 , recorded in 21 cells from β-blocked patients and 31 cells from non-β-blocked patients; several of which (six and nine cells, respectively) were used to record I TO . There was a significant, 34% reduction in peak I K1 , at −120 mV, in myocytes from β-blocked patients, and no significant difference in I K1 at the less negative potentials at which the small outward portion of the current occurred. There was no significant difference in the mean capacity of cells in which I K1 was recorded, between β-blocked and non-β-blocked patients (85±5 vs 87±4 pF; p>0.05). Values are numbers of patients [n; (% of total within group)] with specified clinical characteristics, except for age and heart rate (mean± SEM), in groups of patients not treated, or treated chronically, with a beta adrenoceptor antagonist (β-blocker: no, and β-blocker: yes, respectively). Age and heart rate were compared between groups by unpaired Student's t test; categorical data by χ 2 with Yates' correction CABG coronary artery bypass graft, AVR aortic valve replacement, MVR mitral valve replacement, CCB calcium channel blocker, LVSD left ventricular systolic dysfunction, MI myocardial infarction *p<0.05
Chronic β-blockade did not affect voltage-, time-or rate-dependent properties of human atrial I TO
The voltage dependences of I TO activation and inactivation were not significantly different between myocytes from β-blocked and non-β-blocked patients (Fig. 3a) . Fig. 3b . The mean fast rate constants (inverse of time constants) were 0.16±0.01 for β-blocked patients (22 myocytes, 13 patients) and 0.15±0.01 for non-β-blocked patients (27 myocytes, 15 patients), p>0.05. The corresponding slow rate constants were 0.03±0.01 and 0.04± 0.01, p>0.05, respectively. The contribution of each exponential to I TO inactivation in these cells, i.e., the amplitude of the fast and slow inactivation phases, was also not significantly different (p>0.05 for each phase) between the two patient groups (Fig. 3b inset) . I TO reactivation is shown in Fig. 3c . The mean S 2 I TO current densities were normalised to the first post-rest pulse of the protocol. Initially, at long inter-pulse intervals, I TO density remained unchanged, in keeping with the rapid recovery of I TO from inactivation [11] .
As the inter-pulse interval was shortened to <150 ms, I TO reduced in myocytes from both patient groups. I TO reactivation in 80% of myocytes from β-blocked patients (24 myocytes, 12 patients) and in 93% from non-β-blocked patients (28 myocytes, 13 patients) best fitted a mono-exponential curve (Fig. 3c) . The time course of I TO reactivation for each patient group was virtually superimposable, with mean time constants of reactivation of 33.5±2.6 and 31.3±1.9 ms, respectively; p>0.05. I TO density reduced significantly with increasing stimulation rate; reversible and not different between myocytes from β-blocked and non-β-blocked patients (Fig. 3d) . The reduction in I TO density associated with chronic β-blockade was maintained even at rapid rates.
Acute β-adrenergic stimulation increased atrial I KSUS ; an effect not modified by β-blocker therapy
In atrial cells from a group of patients not treated with a β-blocker, acute superfusion with ISO (1 μM) significantly increased I KSUS and had no significant effect on I K1 or I TO (Fig. 4a) . A similar increase in I KSUS and lack of change in I K1 or I TO was found in response to ISO in cells from a group of patients who were treated chronically with a β-blocker (Fig. 4b ).
Mathematical modelling of human atrial ion current changes associated with chronic β-blockade
Action potentials from the Courtemanche model featured a prominent plateau (phase 2) and a marked "spike and dome" (type 1) morphology (trace i in Fig. 5a ). We progressively reduced the plateau amplitude by sequentially scaling I CaL and I Ksus , until the AP configuration and approximate APD at 90% repolarisation (APD 90 ) as recorded previously in our laboratory in atrial myocytes from non-β-blocked patients [35] was attained: trace ii in Fig. 5a (APD 90 =186 ms). Repeating this simulated AP (trace ii) with I K1 reduced by the same magnitude as observed at −120 mV in the myocytes from β-blocked patients, 34% (Fig. 2) resulted in a 26% increase in APD 90 (Fig. 5b) . A simulated voltage-rampclamp of I K1 indicated that this AP change was due to a reduction in outward I K1 (Fig. 5c) . Reducing I TO independently by 41%, i.e. as associated with β-blocker therapy (Fig. 1c) , also prolonged APD 90 (Fig. 5e ), but by a lesser degree, 9%, than with I K1 reduction. Simultaneous reduction in I K1 and I TO resulted in a 28% increase in APD 90 (Fig. 5f ) versus a 21% increase previously associated with β-blocker therapy [35] . By contrast, using the type 1 AP (nonrepresentative of APs recorded from our laboratory; trace i of Fig. 5a ), the same reductions in I K1 , I TO , and their combination, produced negligible changes in APD 90 : 3% increase, 2% decrease and 2% increase, respectively.
Chronic β-blockade did not reduce mRNA expression of human atrial K + channel subunits Figure 6a -f shows the relative mean abundance of mRNA for Kv4.3, the pore-forming ion channel α-subunit responsible for I TO , and its accessory protein subunits KChIP2, Kvβ1, Kvβ2, KChAP and frequenin [27] . The expression of mRNA for these subunits was not different in the tissue samples from β-blocked patients compared to those from non-β-blocked patients. There was also no change in the expression of Kv1.5, the pore-forming ion channel α-subunit carrying I KSUS [26] (Fig. 6g) . Kir2.1, one of the pore-forming subunits carrying I K1 , tended to increase in the tissue from β-blocked patients (p=0.05; Fig. 6h ) in contrast to the reduction in current density in this patient group. Kir2.2 was not detectable in either group of tissue samples, and there was no change in TWIK-1, the pore-forming subunit of a weak inwardly rectifying current that may contribute to I K1 [19, 26] (Fig. 6i) -sensitive I K1 , in myocytes from patients treated (filled circle, n=21 myocytes, 11 patients) or not treated (empty circle n=31 myocytes, 12 patients) with a β-blocker; *p<0.05
Kv4.3 is highly expressed, and this band was markedly reduced when the antibody was pre-incubated with the Kv4.3 antigen (Fig. 7a) . This polyclonal primary antibody did not detect any similar band in human atrial tissues, presumably because of lower levels of Kv4.3 expression, and hence the monoclonal antibody was then used for increased sensitivity. This monoclonal anti-Kv4.3 also detected Kv4.3 at 65 kDa in the rodent brain tissue positive control, and this band was markedly reduced in rodent lung tissue, in which Kv4.3 expression is minimal [17] (Fig. 7b) . Using this antibody, a band at 65 kDa was also detected in human atrial tissue (Fig. 7b) . The specificity of this antibody was tested by excluding non-specific secondary antibody binding (Fig. 7b) . No antigenic peptide was available for control testing with this monoclonal antibody. Figure 7c shows a Western blot of continuously varying concentrations of total protein from tissue from two β-blocked and two non-β-blocked patients. The blot was cut horizontally just above the 40-kDa marker (dashed horizontal line in Fig. 7c ) prior to incubation with primary antibody. The top half was treated with the monoclonal antiKv4.3 and the bottom with a monoclonal anti-GAPDH that detected GAPDH at 38 kDa. There was no significant difference in the mean optical density (OD) of either GAPDH (9.56±0.70 vs 10.66±1.61 ODu/mm 2 , p>0.05) or Kv4.3 (11.44±1.03 vs 11.57±1.31 ODu/mm 2 , p>0.05) between tissues from β-blocked (n=8) and non-β-blocked (n=10) patients. All ODs were compared at total protein load of 7.5 μg. The ratios of Kv4.3:GAPDH were 1.24±0.13 in samples from β-blocked and 1.30±0.27 in samples from non-β-blocked patients, p>0.05.
Discussion
This is the first study, to our knowledge, to show that the chronic treatment of patients in sinus rhythm with β-blockers is associated with a significant reduction in both atrial I TO and I K1 ; that the reduction in I TO occurred without any changes in its time-, rate-or voltage-dependence; and that neither ion current change resulted from any changes in expression of underlying ion channel subunits. Furthermore, we suggested, using mathematical modelling, that the combination of the reduction in I TO and I K1 may contribute to the established prolongation of atrial action potential repolarisation in patients treated with β-blockers. The magnitude of I TO reduction was similar to that found in a previously reported smaller study by our group [35] , in which other properties of this current were not measured. Further supporting these findings, chronic treatment of rabbits with the β-blocker carvedilol reduced atrial I TO [4] , but no other studies examining the effects on human atrial I TO could be found. However, in catecholaminedepleted rats, and also in rats with chronically reduced cardiac sympathetic innervation, ventricular I TO was reduced in conjunction with prolongation of the APD [2, 21] . Given the rapid inactivation kinetics of I TO , the effect of changes in this current on late repolarisation is presently unclear and under debate [7, 10, 14] . We established that chronic β-blockade in patients was also associated with a reduction in atrial I K1 , measured as the inwardly rectifying Ba 2+ -sensitive current, and this might be expected to prolong action potential terminal repolarisation [12] . Our mathematical modelling of changes in I TO and I K1 suggested that the reduction in each current alone could result in APD prolongation, and also that when combined, these ion current changes could prolong the APD as much as was reported with chronic β-blockade [35] . Of the two currents, I K1 might be expected to contribute more to the APD prolongation. Upregulation of I K1 in chronic AF is considered to be a crucial factor in stabilising the high-frequency rotors that help to sustain fibrillation [28] , and it is conceivable that the present reduction of I K1 seen in patients treated with β-blockers might contribute to their anti-arrhythmic actions by opposing such rotor stabilisation.
We found that pharmacological remodelling by chronic β-blockade was not associated with any change in the expression of the I TO ion channel pore, Kv4.3, either at protein or mRNA level. There was also no change in the expression of mRNA for its related ion channel subunits, although the protein expression of these subunits was not measured. While some accessory subunits, such as KChAP and KChIP2 are involved in trafficking of Kv4.3 to the cell membrane and, therefore, directly influence current density, many subunits modify multiple current characteristics of I TO additional to its density [27] . Therefore, the observed absence of change in the expression of I TO accessory subunits is consistent with the observed absence of change in I TO voltage-and time-dependent characteristics. The reduction in I K1 density was not the result of any significant reduction in mRNA expression of potential pore-forming components, Kir2.1 or TWIK, although neither was examined at protein level as part of this study. We show here ion current changes, by pharmacological remodelling, that did not require changes in the expression of associated ion channel pore-forming or accessory subunits. This appears to contrast with some of the ion current changes which occur in chronic AF [34] that have been associated with changes in expression of corresponding ion channels [9] . However, there are exceptions, e.g. with dramatic changes in I CaL in chronic AF without corresponding changes in protein expression [5, 13, 15, 31] . Perhaps the most likely explanation underlying ion current reduction in the present study is a chronic β-blockade-induced, post-translation alteration in ion channel structure or function. This could result in changes to trafficking of ion channel components to the cell membrane or to their turnover or recycling from the cell membrane or to their interaction with other channel subunits and signalling molecules. The potential of chronic β-blockade to alter phosphorylation-dependent changes in channel function is one possible post-translation modification. Adrenoceptor signalling is complex and varies with chronicity of stimulation. However, cyclic AMP-dependent protein kinase A (PKA), PKC and Ca
2+
-calmodulin-dependent protein kinase II (CaMKII) are all implicated in multiple downstream signalling pathways [37] . In addition, β-adrenoceptors localise to cardiac cell membrane lipid microdomains or caveolae, where they may interact or recruit ion channel subunits [23] . CaMKII has been shown to associate with Kv4.3 and can alter channel function and trafficking to the cell membrane by phosphorylation, as well as affecting gene transcription [27] . Kv4.3 has potential sites for phosphorylation by PKA and PKC, both of which can affect channel function [27] . PKA-dependent phosphorylation has been implicated in localisation of I TO channel complexes in the cell membrane to lipid microdomains via interaction with caveolin-3 [1] . In addition, human cardiac I K1 is also inhibited by both PKC and PKA-dependent signalling pathways [16, 18] . In the present study, acute β-stimulation increased I KSUS and had no effect on I TO or I K1 , consistent with previous reports in human atrium (recently reviewed [32] ). Furthermore, β-blocker therapy did not alter the ISO response of these currents, consistent with a reported lack of effect of β-blocker therapy on I CaL increase by ISO [30] . However, remodelling by β-blocker therapy of other ion current or biochemical responses to β-or α-stimulation, should not be excluded.
Study limitations
We studied cells from patients in sinus rhythm, and it is unknown whether the ability of β-blocker therapy to alter ion currents and action potentials is preserved in cells from patients with chronic AF. It should be noted, however, that β-blockers are used in the treatment of a variety of cardiac pathologies that predispose to AF, including ischaemia, heart failure and hypertension, all of which may cause potentially pro-arrhythmic electrophysiological remodelling [24, 36] . The effects of the potentially anti-arrhythmic remodelling of I TO , I K1 and APD by chronic β-blockade may, therefore, be expected to participate in addition to antiadrenergic, anti-ischaemic and structural remodelling effects of β-blockers. We focussed on I TO , I KSUS and I K1 . I CaL is unaffected by β-blocker therapy [32] , but other currents remain to be studied, e.g. I KACh , I Kr , I Ks and I Na/Ca , as well as intracellular Ca 2+ homeostasis. In the mathematical modelling study, we reduced I K1 by 34%, as was observed at −120 mV, although no change in I K1 was detected at more positive potentials. Inward I K1 is large and easily quantifiable at −120 mV, but it is recognised that outward I K1 at more positive potentials is small, and that the "small expression levels of I K1 indicate that the 'natural variability' between cells may make it difficult to determine how much I K1 is present at plateau potentials" [12] . Any effect of chronic β-blockade to reduce I K1 at such potentials may, therefore, be difficult to discern under voltage clamp conditions. Since cardiac myocytes have a high resistance at the end of the plateau, the APD at this phase is very sensitive to intrinsic net current changes. We therefore considered it important to model a reduction in outward I K1 to investigate potential ionic mechanisms of effects of β-blockade on APD and reasonable to assume a reduction of 34%. However, we do not exclude the possibility that β-blockade decreases I K1 at negative potentials without affecting outward I K1 , through some modification of the voltage sensitivity of I K1 channel gating and that ion current changes additional to the observed reduction in I TO and I K1 are responsible for the increase in APD.
In conclusion, this study improves our understanding of electrophysiological and molecular mechanisms of the potentially anti-arrhythmic prolongation of human atrial action potentials associated with the chronic treatment of patients with β-blockers.
